WO2011015226A1 - Process for the preparation of sterile powdered pharmaceutical compounds in the form of micro and nanoparticles - Google Patents
Process for the preparation of sterile powdered pharmaceutical compounds in the form of micro and nanoparticles Download PDFInfo
- Publication number
- WO2011015226A1 WO2011015226A1 PCT/EP2009/060049 EP2009060049W WO2011015226A1 WO 2011015226 A1 WO2011015226 A1 WO 2011015226A1 EP 2009060049 W EP2009060049 W EP 2009060049W WO 2011015226 A1 WO2011015226 A1 WO 2011015226A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- solvent
- particle size
- sterile
- triamcinolone acetonide
- passed
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
- A61L2/0017—Filtration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
Definitions
- the present invention concerns a process for the preparation of sterile powdered pharmaceutical compounds characterized by narrow particle size distribution.
- the process of the present invention makes use of sterilizing filtration through a 0.22 micron filter followed by treatment with a high pressure homogeniser.
- WO2007/051774 discloses a process for the preparation of sterile powdered pharmaceutical compounds, which process comprises: a) solubilization of the pharmaceutical compound in water or in an organic solvent at a concentration close to saturation; b) sterilizing filtration of the solution by passing it through a hydrophobic filter (0,22 microns membrane); c) evaporating the solvent at constant temperature while subjecting the solution to high intensity ultrasound.
- the process of the present invention comprises the following steps:
- the pharmaceutical compound is solubilized in a solvent and sterilized by filtration;
- step c) the compound is precipitated by evaporation of the solvent and/or by addition of a non-solvent.
- a preferred embodiment of this invention relates to a process for the preparation of a sterile powder pharmaceutical powder characterized by a narrow particle size distribution and by an average particle size by volume comprised between 0.001 ⁇ m and 50 ⁇ m, preferably between 0.005 ⁇ m and 25 ⁇ m.
- the pharmaceutical powdered compound of the present invention is triamcinolone acetonide.
- step d it is possible to influence the average particle size of the powdered compound by changing the process conditions in step d).
- the most important parameters which can be changed in step d are: operating pressure, number of passages and dimension of the interaction chamber.
- an operating pressure of from 50 bar to about 3000 bar is used, more preferably form 200 to 2500 bar.
- the number of passages can also influence the particle size of the powder. When leaving all other conditions unchanged, by increasing the number of passages it is possible to reduce the average particle size of the powder. In general, it is possible to use a number of passages comprised between 1 and 150, more preferably from 1 to 50.
- the dimension of the interaction chamber is another parameter that can be varied in order to influence particle size distribution. A decrease in the size of the interaction chamber will lead to a decrease in the particle size of the powder. Interaction chambers having a size comprised from 30 ⁇ m to 300 ⁇ m are preferred, from 60 ⁇ m to 200 ⁇ m are most preferred.
- the process of the present invention produces, by changing the operative conditions of the homogenizer, powders having different average particle size.
- a pharmaceutical powder preferably triamcinolone acetonide, having conventional size, e.g. average size in volume comprised between 10 and 50 ⁇ m, as well as very fine powders with narrow particle size distribution, e.g. powders having average size in volume comprised between 0.05 and 1.00 ⁇ m, preferably from 0.10 ⁇ m to 0.70 ⁇ m and wherein 90 % by volume of the particles have a diameter equal to or lower than twice the average diameter by volume.
- conventional size e.g. average size in volume comprised between 10 and 50 ⁇ m
- very fine powders with narrow particle size distribution e.g. powders having average size in volume comprised between 0.05 and 1.00 ⁇ m, preferably from 0.10 ⁇ m to 0.70 ⁇ m and wherein 90 % by volume of the particles have a diameter equal to or lower than twice the average diameter by volume.
- Step a) can be performed at room temperature, at high temperature or even at temperatures below room temperature. It is important that the room is classified as class A.
- the filtration of step a) is preferably performed by using a nitrogen pressure of from 0.5 to 1.5 bar. The filtrate is collected in a sterile vessel in a class A room.
- the suspension After precipitation, it is possible to pass the suspension directly into the homogenizer.
- the solvent is optionally removed, either partly or completely. In this case, it is important that the temperature is such that the product is stable and the solvent is volatile. In certain cases, it is possible to apply vacuum to maintain the temperature low.
- the powder is preferably dried for storage.
- the preferred drying method depends on the size of the particles. For particles larger than 1 ⁇ m, it is preferred to filter the suspension by using a
- the dried powder is preferably passed through a sieve with from 70 to 250 micron meshes. In this way, possible agglomerates are removed.
- Fig. 1 shows the particle size distribution of the sterile powder of example 1.
- Fig. 2 shows the particle size distribution of the sterile powder of example 2.
- Fig. 3 shows the particle size distribution of the sterile powder of example 3.
- Fig. 4 shows the particle size distribution of the sterile powder of example 4.
- Fig. 5 shows the particle size distribution of the sterile powder of example 5.
- Fig. 6 shows the particle size distribution of the sterile powder of example 6.
- Fig. 7 shows the particle size distribution of the sterile powder of example 1 before passing the powder in the homogenizer.
- the particle size of the powdered compounds was measured by using a NICOMP 780 Accusizer in the case of particles larger than 1 ⁇ m. For particles having size from 1 nm to 1 ⁇ m, a NICOMP Submicron was used. [0028] Triamcinolone acetonide used in the examples is commercially available from Farmabios.
- the suspension was passed three times in the homogenizer equipped with an interaction chamber of 100 ⁇ m and at a pressure of 1800 bar.
- the suspension is filtered on a 0.45 ⁇ m membrane.
- the solid remaining on the filter is dried in a oven under vacuum.
- the dried powder is then passed on a 70 ⁇ m sieve to remove possible agglomerates.
- the suspension was passed three times in the homogenizer equipped with an interaction chamber of 100 ⁇ m and at a pressure of 1800 bar.
- the suspension is filtered on a 0.45 ⁇ m membrane.
- the solid remaining on the filter is dried in a oven under vacuum.
- the dried powder is then passed on a 70 ⁇ m sieve to remove possible agglomerates.
- Example 3 15 g of triamcinolone acetonide were solubilized in 400 ml of acetone at 50-60 0 C. The solution was filtered through a 0.22 ⁇ m sterilizing filter at 50 0 C and the filtrate collected in a vessel, previously sterilized, while operating in a sterile room (class A). 1000 ml of water for injectable preparations were added at 25°C, under vigorous stirring, to avoid the formation of crystals larger than 200 ⁇ m. Acetone is evaporated by heating the suspension at 35°C under vacuum. The suspension of triamcinolone in water is kept under stirring and passed once through a high pressure homogenizer equipped with an interaction chamber of 200 ⁇ m and at a pressure of 400 bar. The suspension is filtered on a 0.45 ⁇ m membrane. The solid remaining on the filter is dried in a oven under vacuum. The dried powder is then passed on a 70 ⁇ m sieve to remove possible agglomerates.
- Example 4 15 g of triamcinolone acetonide were solubilized in 400 ml of acetone at 50-60 0 C. The solution was filtered through a 0.22 ⁇ m sterilizing filter at 50 0 C and the filtrate collected in a vessel, previously sterilized, while operating in a sterile room (class A). 1000 ml of water for injectable preparations were added at 25°C, under vigorous stirring, to avoid the formation of crystals larger than 200 ⁇ m. The suspension of triamcinolone in water/acetone is kept under stirring and passed once through a high pressure homogenizer equipped with an interaction chamber of 200 ⁇ m and at a pressure of 400 bar. The suspension is filtered on a 0.45 ⁇ m membrane. The solid remaining on the filter is dried in a oven under vacuum. The dried powder is then passed on a 70 ⁇ m sieve to remove possible agglomerates.
- the suspension was passed three times in the homogenizer equipped with an interaction chamber of 100 ⁇ m and at a pressure of 1800 bar. Then, the homogenizer is equipped with an interaction chamber of 87 ⁇ m and the suspension is passed through the homogenizer 8 times at a pressure of 2000 bar. The suspension is then dried under vacuum. The obtained solid is passed on a 70 ⁇ m sieve.
- Example 6 15 g of triamcinolone acetonide were solubilized in 400 ml of acetone at 50-60 0 C. The solution was filtered through a 0.22 ⁇ m sterilizing filter at 50 0 C and the filtrate collected in a vessel, previously sterilized, while operating in a sterile room (class A). 1000 ml of water for injectable preparations were added at 25°C, under vigorous stirring, to avoid the formation of crystals larger than 200 ⁇ m. Acetone is evaporated by heating the suspension at 35°C under vacuum. The suspension of triamcinolone in water is kept under stirring and passed once through a high pressure homogenizer equipped with an interaction chamber of 200 ⁇ m and at a pressure of 400 bar.
- the suspension was passed three times in the homogenizer equipped with an interaction chamber of 100 ⁇ m and at a pressure of 1800 bar. Then, the homogenizer is equipped with an interaction chamber of 87 ⁇ m and the suspension is passed through the homogenizer 22 times at a pressure of 2000 bar. The suspension is then dried under vacuum. The obtained solid is passed on a 70 ⁇ m sieve.
- Example 1 of WO 2007/051774 was repeated.
- a 250 ml one neck round bottomed flask with a thermostatic jacket and a magnetic stirrer containing 140 ml of acetone 2.5 g of triamcinolone acetonide were added.
- the suspension was heated to 50- 60 0 C under stirring until the solid was fully solubilized.
- the solution was then passed through a 0.22 micron filter and collected.
- the solution was kept at 25-30 0 C under vacuum and acetone was evaporated, while the solution was subjected to ultrasound. After complete drying of acetone, the solid was passed through a 70 micron sieve.
- Table 1 shows a comparison of the particle size distribution obtained in example 3, 4 and comparative example 1. It is evident that the use of a high pressure homogenizer leads to a narrower particle size distribution than obtained by using sonication.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Steroid Compounds (AREA)
Abstract
The present invention relates to a process for the preparation of a sterile powdered pharmaceutical compound, the process comprising the following steps: a) the pharmaceutical compound is solubilized in a solvent and sterilized by filtration; b) the filtrate is collected in a sterile vessel in a class A room; c) the pharmaceutical compound is precipitated in a class A room; d) the precipitate suspended in a non-solvent is passed one or more times in a high pressure homogeniser. The invention is also directed to triamcinolone acetonide according to this process, having a narrow particle size distribution and an average particle size by volume comprised between 0.001 μm and 50 μm.
Description
Process for the preparation of sterile powdered pharmaceutical compounds in the form of micro and nanoparticles
[0001] The present invention concerns a process for the preparation of sterile powdered pharmaceutical compounds characterized by narrow particle size distribution. The process of the present invention makes use of sterilizing filtration through a 0.22 micron filter followed by treatment with a high pressure homogeniser.
[0002] Pharmaceutical compounds usually require to be stored in sterile conditions. Sterilization is performed through different methods, e.g. gamma rays or by use of ethylene oxide.
[0003] The use of gamma rays presents the important side effect of degrading part of the product. Furthermore it is an expensive and complex method. Ethylene oxide, on the other hand, requires high temperature and humidity. Also these conditions can cause degradation of the product.
[0004] WO2007/051774 discloses a process for the preparation of sterile powdered pharmaceutical compounds, which process comprises: a) solubilization of the pharmaceutical compound in water or in an organic solvent at a concentration close to saturation; b) sterilizing filtration of the solution by passing it through a hydrophobic filter (0,22 microns membrane); c) evaporating the solvent at constant temperature while subjecting the solution to high intensity ultrasound.
[0005] There is the need for a process which not only results in a sterile powder, but which is also capable of producing a powdered compound with the desired particle size distribution.
[0006] The process of the present invention comprises the following steps:
a) the pharmaceutical compound is solubilized in a solvent and sterilized by filtration;
b) the filtrate is collected in a sterile vessel (class A room);
c) the pharmaceutical compound is precipitated;
d) the precipitate suspended in a non-solvent is passed one or more times in a high pressure homogeniser.
[0007] Preferably, in step c) the compound is precipitated by evaporation of the solvent and/or by addition of a non-solvent.
[0008] A preferred embodiment of this invention relates to a process for the preparation of a sterile powder pharmaceutical powder characterized by a narrow particle size distribution and by an average particle size by volume comprised between 0.001 μm and 50 μm, preferably between 0.005 μm and 25 μm. Preferably, the pharmaceutical powdered compound of the present invention is triamcinolone acetonide.
[0009] In another preferred embodiment of the invention, it is possible to influence the average particle size of the powdered compound by changing the process conditions in step d). The most important parameters which can be changed in step d are: operating pressure, number of passages and dimension of the interaction chamber.
[00010] The higher the operating pressure, the lower will be the average particle size of the powder. Preferably, an operating pressure of from 50 bar to about 3000 bar is used, more preferably form 200 to 2500 bar.
[0010] The number of passages can also influence the particle size of the powder. When leaving all other conditions unchanged, by increasing the number of passages it is possible to reduce the average particle size of the powder. In general, it is possible to use a number of passages comprised between 1 and 150, more preferably from 1 to 50.
[0011] The dimension of the interaction chamber is another parameter that can be varied in order to influence particle size distribution. A decrease in the size of the interaction chamber will lead to a decrease in the particle size of the powder. Interaction chambers having a size comprised from 30 μm to 300 μm are preferred, from 60 μm to 200 μm are most preferred.
[0012] As stated before, the process of the present invention produces, by changing the operative conditions of the homogenizer, powders having different average particle size.
[0013] In fact, by selecting proper process conditions for the high pressure homogenizer, it is possible to prepare a pharmaceutical powder, preferably triamcinolone acetonide, having conventional size, e.g. average size in volume comprised between 10 and 50 μm, as well as very fine powders with narrow particle size distribution, e.g. powders having average size in volume comprised between 0.05 and 1.00 μm, preferably from 0.10 μm to 0.70 μm and wherein 90 % by volume of the particles have a diameter equal to or lower than twice the average diameter by volume.
[0014] Step a) can be performed at room temperature, at high temperature or even at temperatures below room temperature. It is important that the room is classified as class A.
[0015] The filtration of step a) is preferably performed by using a nitrogen pressure of from 0.5 to 1.5 bar. The filtrate is collected in a sterile vessel in a class A room.
[0016] After precipitation, it is possible to pass the suspension directly into the homogenizer. Alternatively, the solvent is optionally removed, either partly or completely. In this case, it is important that the temperature is such that the product is stable and the solvent is volatile. In certain cases, it is possible to apply vacuum to maintain the temperature low.
[0017] After reduction of the particle size in the homogenizer, the powder is preferably dried for storage. The preferred drying method depends on the size of the particles. For particles larger than 1 μm, it is preferred to filter the suspension by using a
0.45 μm membrane. After filtration, the obtained solid is dried under vacuum.
[0018] In the case of nanoparticles, it is impossible to filter them on a membrane and the suspension is either directly dried under vacuum, or it concentrated by using ultrafiltration and then dried under vacuum.
[0019] The dried powder is preferably passed through a sieve with from 70 to 250 micron meshes. In this way, possible agglomerates are removed.
Brief description of the drawings [0020] Fig. 1 shows the particle size distribution of the sterile powder of example 1.
[0021] Fig. 2 shows the particle size distribution of the sterile powder of example 2.
[0022] Fig. 3 shows the particle size distribution of the sterile powder of example 3.
[0023] Fig. 4 shows the particle size distribution of the sterile powder of example 4.
[0024] Fig. 5 shows the particle size distribution of the sterile powder of example 5.
[0025] Fig. 6 shows the particle size distribution of the sterile powder of example 6.
[0026] Fig. 7 shows the particle size distribution of the sterile powder of example 1 before passing the powder in the homogenizer.
Examples
[0027] The particle size of the powdered compounds was measured by using a NICOMP 780 Accusizer in the case of particles larger than 1 μm. For particles having size from 1 nm to 1 μm, a NICOMP Submicron was used.
[0028] Triamcinolone acetonide used in the examples is commercially available from Farmabios.
Example 1
[0024] 15 g of triamcinolone acetonide were solubilized in 400 ml of acetone at 50-60 0C. The solution was filtered through a 0.22 μm sterilizing filter at 50 0C and the filtrate collected in a vessel, previously sterilized, while operating in a sterile room (class A). 1000 ml of water for injectable preparations were added at 25°C, under vigorous stirring, to avoid the formation of crystals larger than 200 μm. Acetone is evaporated by heating the suspension at 35°C under vacuum. The suspension of triamcinolone in water is kept under stirring and passed once through a high pressure homogenizer equipped with an interaction chamber of 200 μm and at a pressure of 400 bar. Then, the suspension was passed three times in the homogenizer equipped with an interaction chamber of 100 μm and at a pressure of 1800 bar. The suspension is filtered on a 0.45 μm membrane. The solid remaining on the filter is dried in a oven under vacuum. The dried powder is then passed on a 70 μm sieve to remove possible agglomerates.
Example 2
[0025] 15 g of triamcinolone acetonide were solubilized in 400 ml of acetone at 50-60 0C. The solution was filtered through a 0.22 μm sterilizing filter at 50 0C and the filtrate collected in a vessel, previously sterilized, while operating in a sterile room (class A). 670 ml of water for injectable preparations were added at 25°C, under vigorous stirring, to avoid the formation of crystals larger than 200 μm. The suspension of triamcinolone in acetone/water is kept under stirring and passed once through a high pressure homogenizer equipped with an interaction chamber of 200 μm and at a pressure of 400 bar. Then, the suspension was passed three times in the homogenizer equipped with an interaction chamber of 100 μm and at a pressure of 1800 bar. The suspension is filtered on a 0.45 μm membrane. The solid remaining on the filter is dried in a oven under vacuum. The dried powder is then passed on a 70 μm sieve to remove possible agglomerates.
Example 3
[0026] 15 g of triamcinolone acetonide were solubilized in 400 ml of acetone at 50-60 0C. The solution was filtered through a 0.22 μm sterilizing filter at 50 0C and the filtrate collected in a vessel, previously sterilized, while operating in a sterile room (class A). 1000 ml of water for injectable preparations were added at 25°C, under vigorous stirring, to avoid the formation of crystals larger than 200 μm. Acetone is evaporated by heating the suspension at 35°C under vacuum. The suspension of triamcinolone in water is kept under stirring and passed once through a high pressure homogenizer equipped with an interaction chamber of 200 μm and at a pressure of 400 bar. The suspension is filtered on a 0.45 μm membrane. The solid remaining on the filter is dried in a oven under vacuum. The dried powder is then passed on a 70 μm sieve to remove possible agglomerates.
Example 4 [0027] 15 g of triamcinolone acetonide were solubilized in 400 ml of acetone at 50-60 0C. The solution was filtered through a 0.22 μm sterilizing filter at 50 0C and the filtrate collected in a vessel, previously sterilized, while operating in a sterile room (class A). 1000 ml of water for injectable preparations were added at 25°C, under vigorous stirring, to avoid the formation of crystals larger than 200 μm. The suspension of triamcinolone in water/acetone is kept under stirring and passed once through a high pressure homogenizer equipped with an interaction chamber of 200 μm and at a pressure of 400 bar. The suspension is filtered on a 0.45 μm membrane. The solid remaining on the filter is dried in a oven under vacuum. The dried powder is then passed on a 70 μm sieve to remove possible agglomerates.
Example 5
[0028] 15 g of triamcinolone acetonide were solubilized in 400 ml of acetone at 50-60 0C. The solution was filtered through a 0.22 μm sterilizing filter at 50 0C and the filtrate collected in a vessel, previously sterilized, while operating in a sterile room (class A). 1000 ml of water for injectable preparations were added at 25°C, under vigorous stirring, to avoid the formation of crystals larger than 200 μm. Acetone is evaporated by heating the suspension at 35°C under vacuum. The suspension of triamcinolone in water is kept under stirring and passed once through a high pressure homogenizer equipped with an
interaction chamber of 200 μm and at a pressure of 400 bar. Then, the suspension was passed three times in the homogenizer equipped with an interaction chamber of 100 μm and at a pressure of 1800 bar. Then, the homogenizer is equipped with an interaction chamber of 87 μm and the suspension is passed through the homogenizer 8 times at a pressure of 2000 bar. The suspension is then dried under vacuum. The obtained solid is passed on a 70 μm sieve.
Example 6 [0029] 15 g of triamcinolone acetonide were solubilized in 400 ml of acetone at 50-60 0C. The solution was filtered through a 0.22 μm sterilizing filter at 50 0C and the filtrate collected in a vessel, previously sterilized, while operating in a sterile room (class A). 1000 ml of water for injectable preparations were added at 25°C, under vigorous stirring, to avoid the formation of crystals larger than 200 μm. Acetone is evaporated by heating the suspension at 35°C under vacuum. The suspension of triamcinolone in water is kept under stirring and passed once through a high pressure homogenizer equipped with an interaction chamber of 200 μm and at a pressure of 400 bar. Then, the suspension was passed three times in the homogenizer equipped with an interaction chamber of 100 μm and at a pressure of 1800 bar. Then, the homogenizer is equipped with an interaction chamber of 87 μm and the suspension is passed through the homogenizer 22 times at a pressure of 2000 bar. The suspension is then dried under vacuum. The obtained solid is passed on a 70 μm sieve.
Comparative example 1
[0030] Example 1 of WO 2007/051774 was repeated. In a 250 ml one neck round bottomed flask with a thermostatic jacket and a magnetic stirrer containing 140 ml of acetone, 2.5 g of triamcinolone acetonide were added. The suspension was heated to 50- 60 0C under stirring until the solid was fully solubilized. The solution was then passed through a 0.22 micron filter and collected. The solution was kept at 25-30 0C under vacuum and acetone was evaporated, while the solution was subjected to ultrasound. After complete drying of acetone, the solid was passed through a 70 micron sieve.
[0031] Table 1 shows a comparison of the particle size distribution obtained in example 3, 4 and comparative example 1. It is evident that the use of a high pressure
homogenizer leads to a narrower particle size distribution than obtained by using sonication.
Table 1
Claims
I. Process for the preparation of a sterile powdered pharmaceutical compound, the process comprising the following steps:
a) The pharmaceutical compound is solubilized in a solvent and sterilized by filtration;
b) the filtrate is collected in a sterile vessel in a class A room;
c) the pharmaceutical compound is precipitated in a class A room; d) the precipitate suspended in a non-solvent is passed one or more times in a high pressure homogeniser.
2. Process according to claim 1 wherein in step c) the compound is precipitated by evaporation of the solvent and/or by addition of a non-solvent.
3. Process according to claim 1 wherein in step c) the compound is precipitated by addition of a non-solvent.
4. Process according to claims 1-3 wherein the non-solvent comprises water.
5. Process according to claims 1-3 wherein the homogenizer is operated at a pressure comprised between 50 and 3000 bar, preferably between 200 and 25000 bar.
6. Process according to claims 1-4 wherein the homogenizer is operated with an interaction chamber of from 30 μm to 300 μm, preferably from 60 μm to 200 μm.
7. Process according to claims 1-6 wherein the suspension is passed in the homogenizer from 1 to 150 times, preferably from 1 to 50 times..
8. Process according to claims 1-7 wherein the pharmaceutical compound is triamcinolone acetonide.
9. Triamcinolone acetonide obtainable according to the process of claim 8.
10. Triamcinolone acetonide according to claim 9, having a narrow particle size distribution and an average particle size by volume comprised between 0.001 μm and 50 μm, preferably between 0.005 μm and 25 μm.
II. Triamcinolone acetonide according to claim 10, having average size in volume comprised between 0.05 and 1.00 μm, preferably from 0.10 μm to 0.70 μm.
12. Triamcinolone acetonide according to claim 11, wherein 90 % by volume of the particles have a diameter equal to or lower than twice the average diameter by volume.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2009/060049 WO2011015226A1 (en) | 2009-08-03 | 2009-08-03 | Process for the preparation of sterile powdered pharmaceutical compounds in the form of micro and nanoparticles |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2009/060049 WO2011015226A1 (en) | 2009-08-03 | 2009-08-03 | Process for the preparation of sterile powdered pharmaceutical compounds in the form of micro and nanoparticles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2011015226A1 true WO2011015226A1 (en) | 2011-02-10 |
Family
ID=41491473
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2009/060049 WO2011015226A1 (en) | 2009-08-03 | 2009-08-03 | Process for the preparation of sterile powdered pharmaceutical compounds in the form of micro and nanoparticles |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2011015226A1 (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990003782A2 (en) * | 1988-10-05 | 1990-04-19 | The Upjohn Company | Finely divided solid crystalline powders via precipitation into an anti-solvent |
| WO2001003670A1 (en) * | 1999-07-13 | 2001-01-18 | Pharmasol Gmbh | Method for controlled production of ultrafine microparticles and nanoparticles |
| WO2003086350A1 (en) * | 2002-04-05 | 2003-10-23 | 3M Innovative Properties Company | Formoterol and mometasone aerosol formulations |
| WO2007051774A2 (en) * | 2005-11-02 | 2007-05-10 | Pharmatex Italia Srl | Process for the preparation of sterile powdered pharmaceutical compounds |
| WO2009021840A1 (en) * | 2007-08-14 | 2009-02-19 | Pharmatex Italia Srl | Injectable pharmaceutical formulation of taxoids |
-
2009
- 2009-08-03 WO PCT/EP2009/060049 patent/WO2011015226A1/en active Application Filing
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990003782A2 (en) * | 1988-10-05 | 1990-04-19 | The Upjohn Company | Finely divided solid crystalline powders via precipitation into an anti-solvent |
| WO2001003670A1 (en) * | 1999-07-13 | 2001-01-18 | Pharmasol Gmbh | Method for controlled production of ultrafine microparticles and nanoparticles |
| WO2003086350A1 (en) * | 2002-04-05 | 2003-10-23 | 3M Innovative Properties Company | Formoterol and mometasone aerosol formulations |
| WO2007051774A2 (en) * | 2005-11-02 | 2007-05-10 | Pharmatex Italia Srl | Process for the preparation of sterile powdered pharmaceutical compounds |
| WO2009021840A1 (en) * | 2007-08-14 | 2009-02-19 | Pharmatex Italia Srl | Injectable pharmaceutical formulation of taxoids |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ramimoghadam et al. | Hydrothermal synthesis of zinc oxide nanoparticles using rice as soft biotemplate | |
| Wang et al. | Stability of nanosuspensions in drug delivery | |
| Gao et al. | Magnetic-responsive microparticles with customized porosity for drug delivery | |
| CN113166552B (en) | Lignin particle-based hydrogels and methods for preparing lignin colloidal particles by solvent evaporation | |
| Urch et al. | Calcium phosphate nanoparticles with adjustable dispersability and crystallinity | |
| CN107555406B (en) | Nano-hydroxyapatite dispersion and preparation process thereof | |
| Semalty et al. | Cyclodextrin inclusion complex of racecadotril: effect of drug-β-cyclodextrin ratio and the method of complexation | |
| EP2156823A1 (en) | Process for the preparation of sterile powdered pharmeceutical compounds in the form of micro and nanoparticles | |
| Nasri et al. | Sardinelle protein isolate as a novel material for oil microencapsulation: Novel alternative for fish by-products valorisation | |
| WO2007051774A2 (en) | Process for the preparation of sterile powdered pharmaceutical compounds | |
| CN107324308B (en) | A kind of mesoporous carbon nanoparticle of core-shell structure and purposes as paclitaxel carrier | |
| WO2011015226A1 (en) | Process for the preparation of sterile powdered pharmaceutical compounds in the form of micro and nanoparticles | |
| EP3843708A2 (en) | Biopolymer based carrier system | |
| Cao et al. | Micro/Nanosized Lignin for Biomedical Application | |
| CN109940168B (en) | Method for rapidly preparing high-salt-tolerance gold nanoparticles | |
| Dzakwan et al. | Nanosized and enhancement of solubility fisetin | |
| CN108864069A (en) | A kind of razaxaban particle and the preparation method and application thereof | |
| CN115159483A (en) | Hydroxyapatite microsphere with adjustable shape and size and preparation method thereof | |
| CN113509450A (en) | Preparation method of calcium ion-stabilized composite nanoparticles for delivering quercetin | |
| Tominaga et al. | The preparation and the sustained release of titanium dioxide hollow particles encapsulating L-ascorbic acid | |
| JP3808086B1 (en) | Thiamine lauryl sulfate crystals and method for producing the same | |
| CN108096218B (en) | A nanometer granule loaded with saikosaponin a and its preparation method | |
| RU2780217C1 (en) | Method for obtaining a fine suspension of hydroxyapatite | |
| KR100885520B1 (en) | Fabrication method of solid particulates and solid particulates prepared by using same | |
| CN107595772B (en) | Preparation method of tacrolimus nano suspension eye drops |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09781438 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 09781438 Country of ref document: EP Kind code of ref document: A1 |